Lifecore Biomedical Inc expected to post a loss of 22 cents a share - Earnings Preview

Lifecore Biomedical

03/08/2026 14:19

Lifecore Biomedical Inc LFCR.OQ LFCR.O is expected to  report resultson August 5 for the period ending June 30 2026
The Chaska Minnesota-based  company is expected to report revenue of $32.016 million, according to the mean estimate from 5 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Lifecore Biomedical Inc is for a loss of 22 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Lifecore Biomedical Inc is $6.50, about 47.1% above its last closing price of $4.42
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.24
-0.24
-0.43
Missed
-79.2
 2026
​
​​
​
This summary was machine generated August 3 at 13:19 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)